CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: John H Brebner, Clayton C Campbell, Anne Jacobson, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Marie Bialek, PharmD — Freelance/Contract Medical Writer: McNeil Consumer & Specialty Pharmaceuticals, Janssen Pharmaceutica Products LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Rini — Consulting Fees and Contracted Research: Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology. Dr Figlin — Consulting Fees: Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Pfizer Inc, Wyeth; Contracted Research: Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, PDL BioPharma Inc, Pfizer Inc, Wyeth. Dr Atkins — Consulting Fees: AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Wilex AG, Wyeth.

---

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

 

 

Home

Interviews
Brian I Rini , MD
- Select publications

Robert A Figlin, MD
- Select publications

MIchael B Atkins , MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office